Investor Relations

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. 

Date Title and Summary
Toggle Summary Juno Therapeutics Names Cindy Elkins as Chief Information Officer
SEATTLE --(BUSINESS WIRE)--Jan. 5, 2018-- Juno Therapeutics , Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Cindy Elkins as Chief Information Officer (CIO).
Toggle Summary Juno Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Jan. 3, 2018-- Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentation at the 36 th Annual J.P. Morgan Healthcare Conference at 4:00 p.m. PT on Tuesday, January 9, 2018 . The presentation will feature a business overview and update by
Toggle Summary Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH
—Updated JCAR017 (liso-cel) data in core group at dose level 2 showed 74% (14/19) ORR and 68% (13/19) CR rate at 3 months, with 50% (7/14) CR at 6 months— —JCAR017 data continue to support better responses at dose level 2 without increased toxicity observed for CRS and NT compared to dose level 1
Toggle Summary Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
—74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2— —Across doses, 80% (16/20) of core group patients in CR at month 3 remain in response at month 6; 92% (11/12) of core group patients in response at 6 months remain in response as of

UPCOMING & PAST EVENTS

View all events

Copyright Nasdaq. Minimum 15 minutes delayed.